Answers are grounded in this paper and cite their sources.
Cardiovascular disease (CVD) remains a major cause of mortality worldwide, and there is an urgent need to develop point‐of‐care (POC) diagnostic tools for rapid, regular, and on‐site monitoring of trace levels of cholesterol in human biological fluids. This work presents a new, reliable, selective, and cost‐effective POC sensor for salivary examination of CVD. An interdigital device is utilized for electronic (capacitive) detection of cholesterol using nanostructured Ag@MoO 3 ‐enhanced molecularly imprinted poly(styrene‐co‐divinylbenzene) in real‐time salivary analysis. The formulation of cholesterol‐imprinted poly(styrene‐co‐divinylbenzene), molecularly imprinted polymer (MIP), and the operational frequency of the devices are precisely optimized. The Ag@MoO 3 ‐MIP sensors exhibit a low limit of detection of 0.03 μM and a limit of quantification of 0.1 μM with an impressive sensitivity of 409 nF μM −1 in the linear range of cholesterol concentration 0.1–2.0 μM. Furthermore, the sensor exhibits excellent selectivity for cholesterol, effectively distinguishing it from other interfering analytes like ascorbic acid, creatinine, guanine, uric acid, and glucose. The recovery outcomes of real‐time spiked saliva samples are within the range of 85.17–98.19%. The sensor's ability to provide reliable, reproducible, and rapid cholesterol analysis in human saliva highlights its potential for early CVD detection and continuous surveillance, leading to improved patient outcomes and more accessible healthcare solutions.
No takes yet. Share an insight, caveat, or question.
Ejaz et al. (2025) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: